**Supplementary Table 1.** Patient demographics and baseline characteristics in the French cohort of the CORRELATE study, stratified by regorafenib starting dose.

|  |  |  |
| --- | --- | --- |
|  | **Starting dose** |  |
|  | **<160 mg (n=108)** | **160 mg (n=134)** | **Total (n=242)** |
| Age, median (range), years | 67 (46–87) | 65 (39–85) | 66 (39–87) |
| Male, n (%) | 68 (63.0) | 79 (59.0) | 147 (60.7) |
| ECOG performance status, n (%) |  |  |  |
| 0 | 27 (25.0) | 54 (40.3) | 81 (33.4) |
| 1 | 62 (57.4) | 58 (43.3) | 120 (49.6) |
| 2–4 | 12 (11.1) | 8 (6.0) | 20 (8.3) |
| missing | 7 (6.5) | 14 (10.5) | 21 (8.7) |
| *KRAS* mutation, n (%) |  |  |  |
| YesNoUnknown | 50 (46.3)54 (50.0)4 (3.7) | 61 (45.5)64 (47.8)9 (6.7) | 111 (45.9)118 (48.8)13 (5.4) |
| *BRAF* mutation, n (%) |  |  |  |
| YesNoUnknown | 6 (5.6)72 (66.7)30 (27.8) | 7 (5.2)84 (62.7)43 (32.1) | 13 (5.4)156 (64.5)73 (30.2) |
| NRAS mutation, n (%) |  |  |  |
| YesNoUnknown | 10 (9.3)55 (50.9)43 (39.8) | 8 (6.0)60 (44.8)66 (49.3) | 18 (7.4)115 (47.5)109 (45.0) |
| Main metastatic sites at regorafenib start, n (%) |  |  |  |
| liver | 82 (75.9) | 106 (79.1) | 188 (77.7) |
| lung | 71 (65.4) | 83 (61.9) | 154 (63.6) |
| peritoneum | 24 (22.2) | 11 (8.2) | 35 (14.5) |
| bone | 9 (8.3) | 14 (10.5) | 23 (9.5) |
| Time from diagnosis of metastatic disease to regorafenib start, median (range), months | 25.6 (<1–102) | 27.8 (2.6––169) | 27.0 (<1–169) |
| Prior systemic anti-cancer therapy, n (%) |  |  |  |
| yes | NA | NA | 240 (99.2) |
| no | NA | NA | 2 (0.8) |
| Number of prior systemic anti-cancer therapies, median (range) | NA | NA | 3 (1–12) |

ECOG PS – Eastern Cooperative Oncology Group performance status; NA: not available.